Tools   Select Another Resource Report Type

http://www.medschool.lsuhsc.edu/neurology/

The Department of Neurology at Louisiana State University Health Sciences Center in New Orleans provides state-of the-art clinical evaluation and care for patients with neurological diseases. Its educational and research programs share the common goals of enhancing the knowledge of neuroscience and improving the diagnosis and care of patients. One of their primary missions is to educate and train medical students, physicians and other health care providers. Their residency and fellowship programs provide physicians with comprehensive training and experience in general and subspecialty neurology. Furthermore, their research programs encompass diverse areas and expertise in neurology and neuroscience. And additionally, many of the department''s faculty have established collaborative multi-disciplinary research projects, especially with members of the LSU Neuroscience Center of Excellence. The Neurology Residency Program at LSU Health Sciences Center is fully accredited by the ACGME. The Department of Neurology is a component of the nationally respected LSU Health Sciences Center, which is the major medical training institution for the State of Louisiana. The LSU Health Sciences has many components, one of which is the Neuroscience Center of Excellence, a state of the art research center for the neurosciences. The LSU Health Sciences Center not only sponsors medical education, but also has a School of Nursing, Dentistry, Physical and Occupational Therapy. This allows for the flourishing of multidisciplinary research and innovative thinking. It accepts three residents per year; residents must complete one year of internal medicine prior to entering into our program. Additionally, LSUHSC Neurology has fellowship available in: - Child Neurology - Pain Management - Neurophysiology

Proper citation: Louisiana State University School of Medicine, Health Sciences Center: Department of Neurology (RRID:SCR_012934) Copy   

•   Source: SciCrunch Registry

http://i2b2.cchmc.org/

A data warehouse that integrates information on patients from multiple sources and consists of patient information from all the visits to Cincinnati Children''''s between 2003 and 2007. This information includes demographics (age, gender, race), diagnoses (ICD-9), procedures, medications and lab results. They have included extracts from Epic, DocSite, and the new Cerner laboratory system and will eventually load public data sources, data from the different divisions or research cores (such as images or genetic data), as well as the research databases from individual groups or investigators. This information is aggregated, cleaned and de-identified. Once this process is complete, it is presented to the user, who will then be able to query the data. The warehouse is best suited for tasks like cohort identification, hypothesis generation and retrospective data analysis. Automated software tools will facilitate some of these functions, while others will require more of a manual process. The initial software tools will be focused around cohort identification. They have developed a set of web-based tools that allow the user to query the warehouse after logging in. The only people able to see your data are those to whom you grant authorization. If the information can be provided to the general research community, they will add it to the warehouse. If it cannot, they will mark it so that only you (or others in your group with proper approval) can access it.

Proper citation: i2b2 Research Data Warehouse (RRID:SCR_013276) Copy   

•   Source: SciCrunch Registry

http://www.siumed.edu/alz/index.html

Resource center that provides assistance for patients and families affected by Alzheimer's disease and related conditions. The Center provides patient care through the Memory and Aging Clinic as well as through research, education and service to the community. Additionally the Center provides training in dementia care, maintains centralized data collection, and sponsors programs of research that qualify for federal financial participation.

Proper citation: SIU Center for Alzheimer's Disease and Related Disorders (RRID:SCR_013199) Copy   

•   Source: SciCrunch Registry

http://www.merge.com

Merge Healthcare Incorporated develops solutions that automate healthcare data and diagnostic workflow to enable a better electronic record of the patient experience, and to enhance product development for health IT, device and pharmaceutical companies. Merge products, ranging from standards-based development toolkits to sophisticated clinical applications, have been used by healthcare providers, vendors and researchers worldwide for over 20 years. Merge Healthcare utilizes decades of technology, expertise, intellectual property, innovative software development and expert services to build IT solutions for healthcare and biopharmaceutical customers worldwide. Merge Healthcares OEM applications and toolkits improve the process of transferring diagnostic data and images, and support integration of data from imaging procedures into broader health IT applications. These solutions provide an advanced start to software development, and are quietly inside many of today''s health IT systems. Merge Healthcares Medical Imaging Solutions bring mission-critical improvements for imaging workflow, from scheduling to billing through disaster recovery. Our Perioperative Solutions provide enhanced workflow for the entire surgery experience. Our customers, from the largest outpatient center chains to rural hospitals, have relied on Merge to bring them the solutions and services needed to run clinically and financially successful businesses. Merge Healthcares eClinical business unit, recently added through the acquisition of etrials Worldwide Inc., provides adaptive web-based tools that coordinate to transform data into intelligence and speed the path to an actionable study endpoint for clinical trials. Pharmaceutical, biotechnology, medical device and contract research organizations use integrated trial, site and patient solutions for real-time access to the high quality data they need to make informed decisions.

Proper citation: Merge Healthcare Incorporated (RRID:SCR_013521) Copy   

•   Source: SciCrunch Registry

http://www.agilent.com/

Company provides laboratories worldwide with analytical instruments and supplies, clinical and diagnostic testing services, consumables, applications and expertise in life sciences and applied chemical markets.

Proper citation: Agilent Technologies (RRID:SCR_013575) Copy   

•   Source: SciCrunch Registry

http://www.cerner.com/

A global health company contributing to the systemic improvement of health care delivery and the health of communities. We are transforming health care by eliminating error, variance and waste for health care providers and consumers around the world. Our solutions optimize processes for health care organizations ranging from single-doctor practices to entire countries, for the pharmaceutical and medical device industries, and for the field of health care as a whole. Our solutions are licensed by more than 9,000 facilities worldwide. We invite you to join us in our quest to make health care become all it should be. Since our company began, we have been committed to transformational change in the vital task of keeping people well. Now more than ever, our focus is on developing the innovations that will help improve the entire health care system. Ultimately, as our CEO Neal Patterson has said, health care is personal. Because in the end, nothing matters more than our health and our families. We''re changing the way people: * Use and share information ** We empower providers to base decisions on best clinical evidence. ** We coordinate care across traditionally fragmented health care systems. ** We provide clinical organizations with the reliability, flexibility and continuous innovation available through cloud-based intelligence. ** We provide contextually relevant information to the right people at the right time. * Pay for health and care ** We believe IT investment must be matched with innovative payment models that are much easier to navigate. ** We are replacing the current, claims-based system with streamlined electronic payments. ** We develop ways to reward people and their providers for proactively achieving positive health goals. * Think about health ** We empower people to actively engage in their health by providing them with a standards-based, lifetime Personal Health Record. ** We are replacing the reactive sick care model with a proactive, personalized plan for health.

Proper citation: Cerner Millenium (RRID:SCR_013581) Copy   

•   Source: SciCrunch Registry

http://www.dbmi.pitt.edu/nlpfront

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 17, 2013. Repository of de-identified clinical reports available for NLP researchers has been designed. Work with the AMIA NLP working group in designing annotation schemas and obtaining annotations, design a repository for shareable annotations, help design and execute a shared task in IE from clinical reports. The University of Pittsburgh NLP Repository contains clinical reports that are available to the community for NLP research purposes and comprises: # Report Repository - one month of de-identified clinical reports from multiple hospitals and # Annotation Repository - annotations performed on reports from the Report Repository. Anyone performing annotations on reports from the NLP Repository is required to deposit their annotations. The Repository contains reports of the following types generated from multiple hospitals during a single month: * History and Physicals * Progress Notes * Consultation Reports * Radiology Reports * Surgical Pathology Reports * Emergency Department Reports * Discharge Summaries * Operative Reports * Cardiology Reports

Proper citation: Open Clinical Report Repository (RRID:SCR_013585) Copy   

•   Source: SciCrunch Registry

http://cordis.europa.eu/project/rcn/98370_en.html

The Colon Therapy Research (COLTHERES) consortium brings together clinical centers and translational researchers funded in the European Union to define and perform biomarker driven clinical trials to improve cancer therapy outcomes. This 4-year consortium will use comprehensively molecularly-annotated colon cancers as a "test-bed" to define specific biomarkers of response or resistance to signaling pathway agents.

Proper citation: Colon Therapy Research Consortium (COLTHERES) (RRID:SCR_013690) Copy   

•   Source: SciCrunch Registry

http://www.cancerimagingarchive.net/

Archive of medical images of cancer accessible for public download. All images are stored in DICOM file format and organized as Collections, typically patients related by common disease (e.g. lung cancer), image modality (MRI, CT, etc) or research focus. Neuroimaging data sets include clinical outcomes, pathology, and genomics in addition to DICOM images. Submitting Data Proposals are welcomed.

Proper citation: Cancer Imaging Archive (TCIA) (RRID:SCR_008927) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org

Diabetes research center which provides patient care and performs diabetes research. Its primary aim is to provide a facilitating framework for conducting multi-disciplinary basic and clinical research and to encourage the scientific development of young investigators.

Proper citation: Joslin Diabetes Center (RRID:SCR_009019) Copy   

•   Source: SciCrunch Registry

http://hub.ucsf.edu/

Portal to resources, expertise, and best practices for investigators, study staff, participants and partners/affiliates to facilitate efficient, compliant and ethical study conduct and management. This collaborative effort across a number of organizations and administrative units was built to leverage existing resources and create new content where readily accessible resources currently don''''t exist. The goals of the HUB are to: * Promote excellence in the quality of clinical research management through education. * Facilitate effective and timely clinical research initiation by improving institutional processes and providing clinical research protocol, regulatory, budget, and financial tools. * Increase awareness of clinical trials in the community through education and community participant recruitment outreach activities. * Interface with institutional/industry partners to support enhanced clinical research practice.

Proper citation: Clinical Research Resource HUB (RRID:SCR_008979) Copy   

•   Source: SciCrunch Registry

https://wiki.nci.nih.gov/display/caGWAS/caGWAS

Too that allows researchers to integrate, query, report, and analyze significant associations between genetic variations and disease, drug response or other clinical outcomes. SNP array technologies make it possible to genotype hundreds of thousands of single nucleotide polymorphisms (SNPs) simultaneously, enabling whole genome association studies. Within the Clinical Genomic Object Model (CGOM), the caIntegrator team created a domain model for Whole Genome Association Study Analysis. CGOM-caGWAS is a A semantically annotated domain model that captures associations between Study, Study Participant, Disease, SNP Association Analysis, SNP Population Frequency and SNP annotations. caGWAS APIs and web portal provide: * a semantically annotated domain model, database schema with sample data, seasoned middleware, APIs, and web portal for GWAS data; * platform and disease agnostic CGOM-caGWAS model and associated APIs; * the opportunity for developers to customize the look and feel of their GWAS portal; * a foundation of open source technologies; * a well-tested and performance-enhanced platform, as the same software is being used to house the CGEMS data portal; * accelerated analysis of results from various biomedical studies; and * a single application through which researchers and bioinformaticians can access and analyze clinical and experimental data from a variety of data types, as caGWAS objects are part of the CGOM, which includes microarray, genomic, immunohistochemistry, imaging, and clinical data.

Proper citation: caGWAS (RRID:SCR_009617) Copy   

•   Source: SciCrunch Registry

http://www.magventure.com

A complete line of non-invasive magnetic stimulation systems designed for clinical examinations and for research in the areas of neurophysiology, neurology, cognitive neuroscience, rehabilitation and psychiatry.

Proper citation: MagVenture: MagPro Magnetic Stimulator (RRID:SCR_009601) Copy   

•   Source: SciCrunch Registry

http://code.google.com/p/neuropsychological-testing-ontology/

An ontology that represents neuropsychological assessments such as the Folstein Mini-Mental State Examination (MMSE), the Trail-Making Test, the Hopkins Verbal Learning Test, and the Wechsler Memory Scale. NPT is designed to allow for the integration of results from a variety of neuropsychological tests that assay similar measures of cognitive functioning and provides a set of classes for the annotation of neuropsychological testing data. Neuropsychological testing is an important component in developing the clinical pictures used in the diagnosis of patients with a range of neurological diseases such as Alzheimer''s disease, multiple sclerosis, and following stroke or traumatic brain injury. An initial goal of the NPT project is to test hypotheses about the diagnosis of Alzheimer''s disease based on the results of neuropsychological assessments. NPT is being built in accordance with the OBO Foundry principles. It is as an extension of the Ontology for Biomedical Investigations (OBI), which utilizes both the Information Artifact Ontology (IAO) and the Basic Formal Ontology (BFO). NPT is a corollary project of the Neurological Disease Ontology (ND) and is being developed in collaboration with the developers of the Mental Functioning Ontology (MF).

Proper citation: Neuropsychological testing ontology (RRID:SCR_010283) Copy   

•   Source: SciCrunch Registry

http://www.usidnet.org/

Research consortium to advance scientific research in the primary immune deficiency diseases (PIDD) and: * Assemble and maintain a registry of patients with primary immunodeficiency diseases to provide a minimum estimate of the prevalence of each disorder in the United States. Provide a comprehensive clinical picture of each disorder and act as a resource for clinical and laboratory research. * Establish a multifaceted mentoring program to introduce new investigators into the field and stimulate interest and research in primary immune deficiency diseases. * Establish an advisory/review committee to maintain a cell/DNA Repository of biologic material from well-characterized PIDD patients for the advancement of scientific research USIDNET operates a large database of patient information for your use. The purpose and scope of this project is to assemble and maintain a registry of residents with primary immunodeficiency diseases. The project was started with the Registry of U.S. Residents with Chronic Granulomatous Disease. Since then, the registry has been expanded and now collects data on all primary immunodeficiency disorders. The following are just a few of the diseases housed in the registry: Chronic Granulomatous Disease, Common Variable Immunodeficiency Disease, DiGeorge Anomaly, Hyper IgM Syndrome, Leukocyte Adhesion Defect, Severe Combined Immunodeficiency Disease, Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia Physicians who would like to register their patients or access the registry are encouraged to contact Onika Davis or Lamar Hamilton, USIDNET team, at odavis (at) primaryimmune.org, or lhamilton (at) primaryimmune.org

Proper citation: USIDNET: US Immunodeficiency Network (RRID:SCR_004672) Copy   

•   Source: SciCrunch Registry

http://caintegrator-info.nci.nih.gov/rembrandt

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on April 28,2023. REMBRANDT is a data repository containing diverse types of molecular research and clinical trials data related to brain cancers, including gliomas, along with a wide variety of web-based analysis tools that readily facilitate the understanding of critical correlations among the different data types. REMBRANDT aims to be the access portal for a national molecular, genetic, and clinical database of several thousand primary brain tumors that is fully open and accessible to all investigators (including intramural and extramural researchers), as well as the public at-large. The main focus is to molecularly characterize a large number of adult and pediatric primary brain tumors and to correlate those data with extensive retrospective and prospective clinical data. Specific data types hosted here are gene expression profiles, real time PCR assays, CGH and SNP array information, sequencing data, tissue array results and images, proteomic profiles, and patients'''' response to various treatments. Clinical trials'''' information and protocols are also accessible. The data can be downloaded as raw files containing all the information gathered through the primary experiments or can be mined using the informatics support provided. This comprehensive brain tumor data portal will allow for easy ad hoc querying across multiple domains, thus allowing physician-scientists to make the right decisions during patient treatments., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Repository of molecular brain neoplasia data (RRID:SCR_004704) Copy   

•   Source: SciCrunch Registry

http://www.bioreclamationivt.com/

BioIVT, formerly BioreclamationIVT, is global provider of biological specimens and services. Provides biological and in vitro products specializing in control and disease state matrices manufactured from human and animal whole blood, plasma, serum, tissues and other fluids which are used in drug discovery, compound development, clinical and research diagnostics., THIS RESOURCE IS NO LONGER IN SERVICE. Documented on September 16,2025.

Proper citation: Bioreclamation (RRID:SCR_004728) Copy   

•   Source: SciCrunch Registry

http://www.capitalbiosciences.com/

Biological products including Cell Immortalization Products, Clinically Defined Human Tissue, cDNA ORF Clones, Premade Adenoviruses, Purified Proteins, Viral Expression Systems and others as well as services like Custom Recombinant Adenovirus Production, Custom Recombinant Lentivirus Production, Protein Detection and Quantification and Stable Cell Line Production for academic and governmental research institutes, pharmaceutical and biotechnology industry. Capital Biosciences offers most types of human tissues, normal and diseased, with extensive clinical history and follow up information. Standard specimen format: Snap-frozen(flash-frozen), Formalin fixed and paraffin embedded (FFPE) tissues, Blood and blood products, Bone marrow, Total RNA, Genomic DNA, Total Proteins, Primary cell cultures, Viable frozen tissue. Tumor tissue samples include: Bladder cancer, Glioblastoma, Medulloblastoma, Breast Carcinoma, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Head and Neck (H&N) Carcinoma, Hepatocellular Carcinoma (HCC), Hodgkin's lymphoma, Kidney, Renal Cell Carcinoma, Lung Cancer, Non-Small Cell (NCSLC), Lung Cancer, Small Cell (SCLC), Melanoma, Mesothelioma, non-Hodgkin's Lymphoma, Ovarian Adenocarcinoma, Pancreatic Cancer, Prostate Cancer, Stomach Cancer.

Proper citation: Capital Biosciences (RRID:SCR_004879) Copy   

•   Source: SciCrunch Registry

http://www.startthecure.com/

South Texas Accelerated Research Therapeutics (START) directs clinical trials of novel anticancer agents using a high quality and innovative information technology infrastructure to ensure accurate and rapid clinical trials in a setting that emphasizes personalized and compassionate clinical care. START''s head office is located in San Antonio, Texas, in the heart of the South Texas Medical Center. With centers located in San Antonio, Texas and Madrid, Spain, START conducts the world''s largest Phase I medical oncology program putting more than 400 patients per year on Phase I trials. Patients travel from all over the world to participate in one or more of our Phase I drug trials. START consists of a team of highly trained physicians and staff with extensive experience in Phase I clinical trials research and are nationally recognized as thought leaders in cancer research and drug development. The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients with cancer. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.

Proper citation: South Texas Accelerated Research Therapeutics (RRID:SCR_004867) Copy   

•   Source: SciCrunch Registry

http://www.meduniwien.ac.at/kin/index.html

The (Clinical) Institute of Neurology (IN) of the Medical University Vienna was founded in 1882 by Heinrich Obersteiner. It is the oldest institution embracing the multidisciplinarity of neurosciences and has served as model for the establishment of similarly designed institutions in many countries. The original location of the then Neurological Institute in Vienna was at Schwarzspanierstrasse. Since 1993, IN is located in the Vienna General Hospital in top-class laboratory facilities. IN is committed to its proud tradition as Obersteiner Institute and to a promising future of a nationally and internationally leading institution in the clinical neurosciences. Our work aims to translate the understanding of nervous diseases to the development of novel therapeutics and diagnostics. IN''''s tasks include diagnostic patient service, research and graduate / postgraduate teaching in neuropathology, neurochemistry, and neuro-molecular biology in an integrated way. Neuropathology is a recognized medical specialty in Austria. It analyzes structural changes of nervous tissues in disease. Diagnostic neuropathology makes use of most modern morphological techniques applied to diseased central, peripheral and vegetative nervous tissues and fluids, and muscle. Neuropathological diagnoses are a basis for disease classification and rational therapies. Neurodegenerative disorders, in particular prion diseases, virus diseases affecting the nervous system, and brain tumors (neuro-oncology) are research priorities. In the highly publicized area of prion diseases, IN has developed into a national and international center of excellence and expertise that leads several European, EU-funded networks in prion research. As an indispensable asset, the IN possesses a large brain bank that has systematically collected neuropathological specimens since 1948. Most samples are fixed and paraffin-embedded tissue only, but in a part of neurosurgical, nerve and muscle biopsies and autopsies, also fresh tissue is obtained, frozen and stored at -80 degrees C. Occasionally blood and CSF are also available. The unique neuropathological collection of histological slides, paraffin blocks and formol-fixed nervous tissues now comprises about 16.000 brain autopsies, 30.000 neurosurgical and 7.500 nerve/muscle biopsies. Also a number of cell cultures have been stored, mainly fibroblasts from patients with rare neurometabolic diseases, and primary cultures of brain tumors. IN participates in the EU-supported European Network of Brain Banks BrainNet Europe.

Proper citation: Medical University of Vienna Institute of Neurology (RRID:SCR_005030) Copy   

•   Source: SciCrunch Registry